Literature DB >> 9511946

The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms.

J S Brar1, K N Chengappa, H Parepally, A R Sandman, S B Kreinbrook, S A Sheth, R Ganguli.   

Abstract

The effectiveness of clozapine in the treatment of the negative symptoms of schizophrenia remains controversial, as improvements in negative symptoms are invariably accompanied by improvements in positive symptoms and neurological side effects. We examined the effectiveness of treatment with clozapine on negative symptoms in a cohort of patients with minimal positive symptoms. Improvements in positive and negative symptoms were measured by BPRS ratings in a subgroup of schizophrenic patients (n=17, from a state hospital cohort of 75) with minimal positive symptoms, who had received clozapine for 6 months. In this subgroup, significant improvements were noted by a composite score on the three negative symptom items of emotional withdrawal, blunted affect, and motor retardation. Positive and depressive symptoms remained unchanged. The remaining cohort (n=58) showed improvements in overall psychopathology including positive, negative, and depressive symptoms. Interestingly, nearly 50% of each group were discharged from the hospital. These findings suggest that clozapine may be beneficial in the treatment of core negative symptoms, even in the absence of other improvements in psychopathology. This effect of clozapine may be a function of its unique pharmacological profile.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9511946     DOI: 10.1023/a:1022352326334

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  9 in total

1.  Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test.

Authors:  Barbara Langen; Rita Dost; Ute Egerland; Hans Stange; Norbert Hoefgen
Journal:  Psychopharmacology (Berl)       Date:  2011-11-16       Impact factor: 4.530

2.  The neurobiology of transition to psychosis: clearing the cache.

Authors:  Lena Palaniyappan; Tushar Das; Kara Dempster
Journal:  J Psychiatry Neurosci       Date:  2017-09       Impact factor: 6.186

3.  The Atypical Antipsychotic Agent, Clozapine, Protects Against Corticosterone-Induced Death of PC12 Cells by Regulating the Akt/FoxO3a Signaling Pathway.

Authors:  Zhiwen Zeng; Xue Wang; Sanjeev K Bhardwaj; Xuanhe Zhou; Peter J Little; Remi Quirion; Lalit K Srivastava; Wenhua Zheng
Journal:  Mol Neurobiol       Date:  2016-05-13       Impact factor: 5.590

Review 4.  Clozapine versus typical neuroleptic medication for schizophrenia.

Authors:  Adib Essali; Nahla Al-Haj Haasan; Chunbo Li; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 5.  Rare and very rare adverse effects of clozapine.

Authors:  Pasquale De Fazio; Raffaele Gaetano; Mariarita Caroleo; Gregorio Cerminara; Francesca Maida; Antonio Bruno; Maria Rosaria Muscatello; Maria Jose Jaén Moreno; Emilio Russo; Cristina Segura-García
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-06       Impact factor: 2.570

6.  Clozapine: Improvement of Negative Symptoms of Schizophrenia.

Authors:  Afaque H Khan; Samina Zaidi
Journal:  Cureus       Date:  2017-12-20

Review 7.  Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques.

Authors:  Ginetta Collo; Armida Mucci; Giulia M Giordano; Emilio Merlo Pich; Silvana Galderisi
Journal:  Front Neurosci       Date:  2020-06-18       Impact factor: 4.677

Review 8.  Antipsychotic Drug Development: From Historical Evidence to Fresh Perspectives.

Authors:  Katrina Weston-Green
Journal:  Front Psychiatry       Date:  2022-06-16       Impact factor: 5.435

9.  Clozapine interaction with phosphatidyl inositol 3-kinase (PI3K)/insulin-signaling pathway in Caenorhabditis elegans.

Authors:  Rakesh Karmacharya; Gregory R Sliwoski; Miriam Y Lundy; Raymond F Suckow; Bruce M Cohen; Edgar A Buttner
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.